doctor on phone - Referrals for Clinicians

How We Work With Therapists & Healthcare Providers

How We Work With Therapists & Healthcare Providers

In our experience, patients are best served when the all members of the provider team work together and are fully informed. We value your expertise and welcome the opportunity to support you and your patients.

maxresdefault - Referrals for Clinicians

We Work With:

  • Psychiatrists
  • Therapists
  • Psychologists
  • Neurologists
  • Pain Specialists
  • Primary Care Physicians
  • Coaches
  • Social Workers

Treatments for:

  • Depression
  • Anxiety
  • PTSD
  • Migraines & Headaches
  • CRPS & Chronic Pain
  • Immunity & Resilience

Our Services:

  • IV Ketamine
  • IV NAD+
  • IV Nutrients & Vitamins
  • Intranasal Ketamine & NAD+
  • IV Glutathione
  • Ketamine Assisted Psychotherapy (KAP)

Let us help you support your patients!

We pride ourselves on offering our patients a process that is administratively efficient and clinically rigorous while maintining a high level of personalized care and attention.

Step 1: Confirm Your Patient's Interest

The first step is to confirm your patient's openness/interest in infusion therapies such as Ketamine, NAD+, Vitamins, Glutathione, etc. by having a conversation with the differences between Combination Infusion Therapy and conventional approaches to treating anxiety, depression and PTSD.

Step 2: Submit Online Patient Referral Form

If you believe your patient may be a good fit for guided Ketamine treatments, then please tell us a little about them so we may contact them. You can submit a Patient Referral Form here.

Step 3: Review Patient Care Plan With Us

Once we have spoken with your patient and received required documents, we will contact you to confirm/discuss our treatment plan. We value your input and experience and will work closely with you to ensure the best patient care possible.

Step 4: We Provide Ongoing Updates About Treatments and Progress

With your patient's consent, we will share treatment information with you in order to keep you informed of their progress.

WE CAN HELP

Refer Your Patient To Us

If you are a doctor or therapist with a patient you think could benefit from Combination Infusion Therapy, then please submit our referral form.

Latest Science & Research

Portrait of woman holding black and white younger photo of herself - Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age

Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age

January 14, 2014

High levels of oxidative damage results in key cellular changes including a reduction in available nicotinamide adenine dinucleotide (NAD+), an essential molecule required for a number of vital cellular processes including DNA repair, immune signaling and epigenetic processing.

Read More
Artificial-Synapse - Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression

October 1, 2013

Ketamine, a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression.

Read More
OCD1 - Ketamine to Treat Obsessive-Compulsive Disorder (OCD)

Ketamine to Treat Obsessive-Compulsive Disorder (OCD)

July 17, 2013

As converging evidence suggests a role for the glutamate system in the pathophysiology of OCD, we tested whether a single dose of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, could achieve rapid antiobsessional effects.

Read More
Screen Shot 2021-02-11 at 11.51.52 AM - Ketamine and Depression: From Despair to Hope in Hours

Ketamine and Depression: From Despair to Hope in Hours

April 4, 2013

Carlos Zarate, M.D., speeds up treatment for major depression at the National Institutes of Health (NIH) Intramural Research Program (IRP). Dr. Zarate is Chief of the Experimental Therapeutics & Pathophysiology Branch and the Section on the Neurobiology and Treatment of Mood Disorders at the National Institute of Mental Health (NIMH).

Read More
Scroll to Top